NEOG NEOGEN CORP
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 711377 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.3%
TTM net income YoY94.6%
TTM EPS YoY94.6%
Revenue 3-yr CAGR-1.3%
Net income 3-yr CAGR—
Margins
Gross margin47.4%
Operating margin-0.8%
Net margin-6.3%
FCF margin5.6%
EBITDA margin12.3%
Returns
ROE-2.7%
ROA-1.7%
ROIC (approx.)-0.2%
Asset turnover0.26x
Leverage & solvency
Liabilities / assets36.8%
Debt / equity0.74x
Current ratio3.90x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.52x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 | FY20242024-05-31 | FY20232023-05-31 | FY20222022-05-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $870.40M | $894.66M | $924.20M | $822.45M | $527.16M |
| Cost of revenue | $461.90M | $473.30M | $460.30M | $416.49M | $284.15M |
| Gross profit | $408.50M | $421.40M | $463.90M | $405.95M | $243.01M |
| R&D expense | $18.40M | $21.10M | $22.50M | $26.04M | $17.05M |
| SG&A expense | $245.10M | $218.20M | $199.90M | $201.18M | $82.74M |
| Operating income | -$21.60M | -$1.06B | $58.60M | $37.52M | $58.62M |
| Interest expense | $24.10M | $38.10M | $42.15M | $27.25M | — |
| Pretax income | -$9.00M | -$1.13B | -$14.30M | -$22.04M | $60.21M |
| Income tax | -$1.10M | -$41.10M | -$4.90M | $828,000 | $11.90M |
| Net income | -$7.90M | -$1.09B | -$9.40M | -$22.87M | $48.31M |
| EBITDA | $94.70M | -$941.50M | $175.30M | $125.89M | $82.31M |
| EPS (basic) | -0.04 | -5.03 | -0.04 | -0.12 | 0.45 |
| EPS (diluted) | -0.04 | -5.03 | -0.04 | -0.12 | 0.45 |
| Weighted avg. shares (diluted) | 217.50M | 216.90M | 216.50M | 188.88M | 108.02M |
| Balance sheet | |||||
| Cash & equivalents | $185.50M | $129.00M | $170.60M | $163.20M | $44.47M |
| Short-term investments | — | $0 | $325,000 | $82.33M | $336.58M |
| Receivables | $146.80M | $153.40M | $173.00M | $153.25M | $99.67M |
| Inventory | $144.30M | $190.80M | $189.27M | $133.81M | $122.31M |
| Current assets | $604.60M | $576.90M | $589.23M | $585.93M | $626.80M |
| PP&E, net | $329.80M | $339.10M | $277.10M | $198.75M | $110.58M |
| Goodwill | $1.05B | $1.06B | $2.14B | $2.14B | $142.70M |
| Intangibles | $1.32B | $1.41B | $1.51B | $1.59B | $92.11M |
| Total assets | $3.35B | $3.44B | $4.55B | $4.55B | $992.93M |
| Current liabilities | $158.20M | $174.00M | $154.32M | $145.47M | $77.84M |
| Short-term debt | $800.00M | $19.30M | $2.45M | $900.00M | — |
| Long-term debt | $793.70M | $874.80M | $888.39M | $885.44M | $0 |
| Total debt | $1.59B | $894.10M | $890.84M | $1.79B | $0 |
| Total liabilities | $1.25B | $1.37B | $1.40B | $1.42B | $105.56M |
| Shareholders' equity | $2.09B | $2.07B | $3.14B | $3.13B | $887.37M |
| Net debt | $1.41B | $765.10M | $720.24M | $1.62B | -$44.47M |
| Shares outstanding | 217.70M | 217.00M | 217.04M | 216.25M | 107.80M |
| Cash flow statement | |||||
| Operating cash flow | $83.20M | $58.20M | $35.30M | $41.03M | $68.04M |
| Capital expenditure | $51.30M | $104.60M | $111.40M | $65.76M | $24.43M |
| Free cash flow | $31.90M | -$46.40M | -$76.10M | -$24.73M | $43.61M |
| Investing cash flow | $70.50M | -$99.20M | -$29.30M | $201.04M | -$97.23M |
| Financing cash flow | -$99.40M | -$1.60M | $1.90M | -$118.08M | $6.81M |
| Depreciation & amortization | $116.30M | $119.50M | $116.70M | $88.38M | $23.69M |
| Stock-based compensation | $13.40M | $17.30M | $13.80M | $10.18M | $7.15M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.